Market closed

Seres Therapeutics/$MCRB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Ticker

$MCRB
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

233
Website
www.serestherapeutics.com

MCRB Metrics

BasicAdvanced
$141M
-
-$0.18
2.05
-

$141M

2.05

$1.53

$0.54

2.2M

1.125

1.031

356.478

391.371

-3.96%

-9.70%

-1,556.28%

0.945

5.86

5.86

-0.754

12,856.41%

-84.25%

-6.65%

-22.17%

What the Analysts think about MCRB

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Seres Therapeutics stock.

MCRB Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MCRB Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

MCRB News

AllArticlesVideos
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

GlobeNewsWire·6 days ago
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

GlobeNewsWire·2 months ago
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MCRB

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Seres Therapeutics stock?

Seres Therapeutics (MCRB) has a market cap of $141M as of January 15, 2025.

What is the P/E ratio for Seres Therapeutics stock?

The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 0 as of January 15, 2025.

Does Seres Therapeutics stock pay dividends?

No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Seres Therapeutics dividend payment date?

Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.

What is the beta indicator for Seres Therapeutics?

Seres Therapeutics (MCRB) has a beta rating of 2.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.